Vyome Holdings, Inc HIND
Lifesciences Inc. (now known as Vyome Holdings, Inc.) (the "Company") completed the merger pursuant to the Agreement and Plan
of Merger, dated as of July 8, 2024, as amended (the "Merger Agreement"), by and among the Company, Raider Lifesciences Inc.,
a wholly owned subsidiary of the Company ("Merger Sub"), and Vyome Therapeutics, Inc. ("Vyome"). Pursuant to the
Merger Agreement, Merger Sub merged with and into Vyome, with Vyome surviving the merger as a subsidiary of the Company (the "Merger").
Last close
2.22
2026-09-04
Market cap
$15.6M
2026-06-30 share count
52-week range
1.75 - 9.56
Valuation FY2025 figures against the last close
P/S48.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-4.86
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $319.7K | $256.9K | $8.7M | $11.2M | $13.6M | $11.3M | $3.3M | $9.1M | $9.9M | $3.4M |
| Cost of revenue | $100.9K | $62.0K | $3.1M | $4.4M | $5.3M | $5.0M | $3.0M | $5.4M | $4.8M | $2.8M |
| Gross profit | $218.8K | $195.0K | $5.5M | $6.8M | $8.3M | $6.3M | $331.0K | $3.7M | $5.1M | $584.0K |
| R&D | $588.3K | $285.4K | $2.3M | $2.5M | $2.4M | $3.5M | $6.9M | $10.7M | $10.6M | $9.9M |
| SG&A | $2.4M | $898.6K | $10.3M | $14.1M | $8.9M | $4.7M | $16.7M | $29.9M | $28.8M | $10.2M |
| Total operating expenses | $10.7M | $1.2M | $20.9M | $53.2M | $66.2M | $18.7M | $23.6M | $40.6M | $39.5M | $20.1M |
| Operating income | -$10.5M | -$1.0M | -$15.4M | -$46.4M | -$57.9M | -$12.5M | -$23.2M | -$37.0M | -$34.4M | -$19.5M |
| Interest expense | $146.6K | $206.0K | — | — | — | — | — | — | — | — |
| Pre-tax income | — | -$7.1M | -$11.3M | -$46.6M | -$63.4M | -$21.8M | -$23.7M | -$37.4M | -$34.8M | -$20.5M |
| Income tax | — | $39.0K | $52.0K | $380.0K | $274.0K | $181.0K | $14.0K | $11.0K | $10.0K | $2.0K |
| Net income | -$10.3M | -$1.4M | -$11.4M | -$46.2M | -$63.1M | -$21.6M | -$23.7M | -$37.4M | -$34.8M | -$20.5M |
| EPS, basic | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 | -5.54 | — | — | — | — |
| EPS, diluted | -4.86 | -6,001.39 | -110.87 | -108.90 | -288.97 | -5.54 | -5.03 | -19.64 | -2.08 | -4.85 |
| Shares, diluted (wtd. avg.) | $2.2M | $241 | $102.7K | $424.4K | $218.5K | $3.9M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.0M | $101.9K | $16.6K | $4.0M | $22.8M | $3.0M | $3.0M | $21.2M | $21.1M | $73.0M |
| Short-term investments | — | — | — | — | — | — | $0 | $2.5M | $23.3M | $2.5M |
| Receivables | $325 | $2.3K | $1.7M | — | — | — | $285.0K | $870.0K | $4.2M | $0 |
| Inventory | — | $2.5M | $3.7M | $3.6M | $3.0M | $2.2M | $1.9M | $1.6M | $1.4M | $827.0K |
| Total current assets | $5.4M | $302.0K | $10.3M | $9.9M | $65.3M | $8.9M | $18.2M | $28.6M | $51.8M | $78.1M |
| Property, plant and equipment | $46.4K | $59.2K | $60.0K | $698.0K | $1.5M | $584.0K | $1.1M | $1.7M | $1.3M | $717.0K |
| Goodwill | — | — | — | — | $23.5M | — | — | — | — | — |
| Other intangibles | $314.2K | $314.2K | — | $260.0K | $13.9M | $12.9M | — | — | — | — |
| Total assets | $6.5M | $1.4M | $10.7M | $11.1M | $120.0M | $37.1M | $20.4M | $30.4M | $53.1M | $78.8M |
| Accounts payable | $647.5K | $501.9K | $1.7M | $1.9M | $3.5M | $3.7M | $648.0K | $1.2M | $1.3M | $595.0K |
| Short-term debt | — | $811.0K | — | — | — | $3.6M | $0 | $9.9M | $2.0M | $0 |
| Total current liabilities | $2.7M | $5.7M | $3.8M | $7.5M | $7.5M | $11.6M | $4.0M | $17.2M | $10.0M | $4.6M |
| Long-term debt | — | — | — | — | — | $9.2M | — | $0 | $8.0M | $9.9M |
| Total liabilities | $2.7M | $5.8M | $4.0M | $7.5M | $8.2M | $22.6M | $4.5M | $17.3M | $18.0M | $14.5M |
| Retained earnings | -$87.6M | -$55.4M | -$635.6M | -$624.2M | -$523.6M | -$514.8M | -$172.4M | -$148.8M | -$111.4M | -$76.6M |
| Total equity | $3.8M | -$4.4M | -$6.2M | $3.7M | $44.3M | $14.5M | $24.1M | $13.1M | $35.1M | $64.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.7M | -$614.1K | -$17.0M | -$21.9M | -$15.4M | -$8.6M | -$22.9M | -$29.4M | -$30.6M | -$19.4M |
| Depreciation and amortisation | — | $22.0K | $121.0K | $330.0K | $232.0K | $15.0K | $400.0K | — | — | — |
| Stock-based compensation | $577.1K | $184.0K | $766.0K | $2.1M | $12.2M | $1.3M | $3.0M | $4.7M | $3.2M | $563.0K |
| Capital expenditure | — | — | $43.0K | $131.0K | $352.0K | $390.0K | $194.0K | $1.3M | $1.0M | $352.0K |
| Investing cash flow | — | $315 | -$10.0K | -$92.0K | $1.9M | -$2.4M | $2.4M | $19.5M | -$21.9M | $6.2M |
| Financing cash flow | $8.7M | $698.0K | $17.6M | $3.1M | $33.3M | $11.1M | $13.4M | $10.0M | $613.0K | $82.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-029500.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |